FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386226179> ?p ?o ?g. }

• W4386226179 endingPage "e076843" @default.
• W4386226179 startingPage "e076843" @default.
• W4386226179 abstract "Women-controlled HIV prevention technologies that overcome adherence challenges of available daily oral pre-exposure prophylaxis and give women a choice of options are urgently needed. Broadly neutralising monoclonal antibodies (bnAbs) administered passively may offer a valuable non-antiretroviral biological intervention for HIV prevention. Animal and human studies have demonstrated that bnAbs which neutralise HIV can prevent infection. The optimal plasma antibody concentrations to confer protection against HIV infection in humans is under intense study. The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 012C trial will evaluate extended safety and pharmacokinetics of CAP256V2LS and VRC07-523LS among young HIV-negative South African and Zambian women. The study design also allows for an evaluation of a signal of HIV prevention efficacy.CAPRISA 012 is a series of trials with three distinct protocols. The completed CAPRISA 012A and 012B phase 1 trials provided critical data for the CAPRISA 012C trial, which is divided into parts A and B. In part A, 90 participants were randomised to receive both CAP256V2LS and VRC07-523LS at 20 mg/kg or placebo, subcutaneously every 16 or 24 weeks. Part B will enrol 900 participants in South Africa and Zambia who will be randomised in a 1:1 ratio and receive an initial loading dose of 1.2 g of CAP256V2LS and VRC07-523LS or placebo followed by 600 mg of CAP256V2LS and 1.2 g of VRC07-523LS or placebo subcutaneously every 6 months. Safety will be assessed by frequency and severity of reactogenicity and other related adverse events. Pharmacokinetics of both antibodies will be measured in systemic and mucosal compartments over time, while participants will be monitored for breakthrough HIV infections.The University of KwaZulu-Natal Biomedical Research Ethics Committee and South African Health Products Regulatory Authority have approved the trial (BREC/00002492/2021, SAHPRA20210317). Results will be disseminated through conference presentations, peer-reviewed publications and the clinical trial registry.PACTR202112683307570." @default.
• W4386226179 created "2023-08-29" @default.
• W4386226179 creator A5007528258 @default.
• W4386226179 creator A5016501067 @default.
• W4386226179 creator A5016771456 @default.
• W4386226179 creator A5020230187 @default.
• W4386226179 creator A5023679271 @default.
• W4386226179 creator A5028814618 @default.
• W4386226179 creator A5030822254 @default.
• W4386226179 creator A5033512341 @default.
• W4386226179 creator A5034685679 @default.
• W4386226179 creator A5038341964 @default.
• W4386226179 creator A5038944401 @default.
• W4386226179 creator A5040076878 @default.
• W4386226179 creator A5042296790 @default.
• W4386226179 creator A5045255494 @default.
• W4386226179 creator A5058180756 @default.
• W4386226179 creator A5058390834 @default.
• W4386226179 creator A5060315572 @default.
• W4386226179 creator A5066848750 @default.
• W4386226179 creator A5067136189 @default.
• W4386226179 creator A5068843080 @default.
• W4386226179 creator A5070401852 @default.
• W4386226179 creator A5071642396 @default.
• W4386226179 creator A5072177363 @default.
• W4386226179 creator A5075725183 @default.
• W4386226179 creator A5090023210 @default.
• W4386226179 creator A5092708930 @default.
• W4386226179 creator A5092708931 @default.
• W4386226179 date "2023-08-01" @default.
• W4386226179 modified "2023-09-27" @default.
• W4386226179 title "Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial" @default.
• W4386226179 cites W1952332830 @default.
• W4386226179 cites W2005475183 @default.
• W4386226179 cites W2010959676 @default.
• W4386226179 cites W2015186160 @default.
• W4386226179 cites W2028631987 @default.
• W4386226179 cites W2044369525 @default.
• W4386226179 cites W2108422942 @default.
• W4386226179 cites W2113822425 @default.
• W4386226179 cites W2129482488 @default.
• W4386226179 cites W2135847964 @default.
• W4386226179 cites W2146634980 @default.
• W4386226179 cites W2168251450 @default.
• W4386226179 cites W2179136778 @default.
• W4386226179 cites W2181008927 @default.
• W4386226179 cites W2187550429 @default.
• W4386226179 cites W2290010664 @default.
• W4386226179 cites W2294858472 @default.
• W4386226179 cites W2324835369 @default.
• W4386226179 cites W2475857717 @default.
• W4386226179 cites W2557801288 @default.
• W4386226179 cites W2558446330 @default.
• W4386226179 cites W2581209976 @default.
• W4386226179 cites W2751251539 @default.
• W4386226179 cites W2799481439 @default.
• W4386226179 cites W2955800002 @default.
• W4386226179 cites W2970905849 @default.
• W4386226179 cites W3006954854 @default.
• W4386226179 cites W3039215568 @default.
• W4386226179 cites W3086584507 @default.
• W4386226179 cites W3108432543 @default.
• W4386226179 cites W3138945586 @default.
• W4386226179 cites W3173983975 @default.
• W4386226179 cites W3190424399 @default.
• W4386226179 cites W4200094957 @default.
• W4386226179 cites W4210527405 @default.
• W4386226179 cites W4292641516 @default.
• W4386226179 cites W4307389560 @default.
• W4386226179 cites W4361195527 @default.
• W4386226179 doi "https://doi.org/10.1136/bmjopen-2023-076843" @default.
• W4386226179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37640457" @default.
• W4386226179 hasPublicationYear "2023" @default.
• W4386226179 type Work @default.
• W4386226179 citedByCount "0" @default.
• W4386226179 crossrefType "journal-article" @default.
• W4386226179 hasAuthorship W4386226179A5007528258 @default.
• W4386226179 hasAuthorship W4386226179A5016501067 @default.
• W4386226179 hasAuthorship W4386226179A5016771456 @default.
• W4386226179 hasAuthorship W4386226179A5020230187 @default.
• W4386226179 hasAuthorship W4386226179A5023679271 @default.
• W4386226179 hasAuthorship W4386226179A5028814618 @default.
• W4386226179 hasAuthorship W4386226179A5030822254 @default.
• W4386226179 hasAuthorship W4386226179A5033512341 @default.
• W4386226179 hasAuthorship W4386226179A5034685679 @default.
• W4386226179 hasAuthorship W4386226179A5038341964 @default.
• W4386226179 hasAuthorship W4386226179A5038944401 @default.
• W4386226179 hasAuthorship W4386226179A5040076878 @default.
• W4386226179 hasAuthorship W4386226179A5042296790 @default.
• W4386226179 hasAuthorship W4386226179A5045255494 @default.
• W4386226179 hasAuthorship W4386226179A5058180756 @default.
• W4386226179 hasAuthorship W4386226179A5058390834 @default.
• W4386226179 hasAuthorship W4386226179A5060315572 @default.
• W4386226179 hasAuthorship W4386226179A5066848750 @default.
• W4386226179 hasAuthorship W4386226179A5067136189 @default.
• W4386226179 hasAuthorship W4386226179A5068843080 @default.
• W4386226179 hasAuthorship W4386226179A5070401852 @default.
• W4386226179 hasAuthorship W4386226179A5071642396 @default.

• next